Transthyretin Amyloidosis Treatment Market Size

Transthyretin Amyloidosis Treatment Market size was valued at USD 5.9 billion in 2023 and is expected to reach USD 11.2 billion by 2032, growing at a CAGR of 7.5% over the analysis period. Increasing prevalence of transthyretin amyloidosis, a rare genetic disorder, coupled with advancements in treatment options for rare diseases are fuelling market expansion.

Additionally, as the disease is more common in older individuals, rising aging population, particularly in developed countries, is contributing to market growth. For instance, wild-type transthyretin amyloidosis (ATTRwt) mainly affects older men, and certain autopsy studies have shown that 25% of patients aged above 80 years old have transthyretin amyloid myocardial deposits. Thus, as the global geriatric population rises, the incidence rates of transthyretin amyloidosis disease are expected to increase, thereby fostering the market growth.

Transthyretin amyloidosis (ATTR) treatment refers to the medical interventions aimed at managing and slowing the progression of ATTR amyloidosis, a rare, progressive, and often fatal disease caused by the buildup of abnormal transthyretin protein in tissues and organs. Treatment approaches include medications to stabilize or reduce the production of transthyretin and supportive therapies to manage symptoms and complications.